Skip to main content
Premium Trial:

Request an Annual Quote

David Sidransky, James Szabo, Steven Godin, Kory Engelke

Biosimulation firm Optimata has appointed David Sidransky to its scientific advisory board. Sidransky is the director of the head and neck cancer research division at Johns Hopkins University School of Medicine. He is also a professor of oncology, otolaryngology-head and neck surgery, cellular and molecular medicine, urology, genetics, and pathology at John Hopkins University and Hospital. He is a director of Imclone and Alfacell and has served on the scientific advisory boards of Medimmune, Telik, Roche, and Amgen.

Gene Logic has promoted James Szabo to vice president of toxicology services and Steven Godin to senior director of general toxicology. The company has also hired Kory Engelke as senior director of general toxicology. Szabo has been with Gene Logic since 2004, and has held several positions in pathology and toxicology. Prior to joining Gene Logic, he worked for eight years at Dow Chemical. Godin also joined Gene Logic in 2004. Prior to that, he served as a senior study director at MPI Research, director of toxicology at White Eagle Toxicology Laboratories, manager of drug metabolism at Cephalon, and project scientist for ManTech Environmental. Engelke, a board-certified toxicologist, joins the firm from Sucampo Pharmaceuticals.

Filed under

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.